SCHEDULE 13G: Maverick Capital Discloses 5.2% Passive Stake in Rocket Pharmaceuticals

Maverick Capital, Ltd., along with its affiliates, has disclosed a 5.2% beneficial ownership stake in Rocket Pharmaceuticals, Inc., holding 5,547,175 shares of common stock.

Summary

• Maverick Capital, Ltd., Maverick Capital Management, LLC, and Lee S. Ainslie III collectively reported beneficial ownership of 5,547,175 shares of Rocket Pharmaceuticals, Inc. common stock.
• This ownership represents 5.2% of the company's total outstanding common stock.
• The percentage is calculated based on 106,629,701 outstanding shares of Rocket Pharmaceuticals, Inc., as reported in the issuer's Annual Report on Form 10-K filed with the SEC on February 27, 2025.
• The shares are held for the accounts of Maverick's clients, including Maverick Fund USA, Ltd. (1,224,879 Shares), Maverick Fund II, Ltd. (1,123,016 Shares), Maverick Long Enhanced Fund, Ltd (1,231,492 Shares), Maverick HP, L.P. (1,089,675 Shares), Maverick Long Fund, Ltd. (640,852 Shares), and certain separately managed accounts (237,261 Shares).
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, compliance-driven disclosure of beneficial ownership and does not convey positive or negative sentiment regarding the issuer's performance or prospects. It is neutral in tone and content.

Positives

• The disclosure of a significant stake by a reputable institutional investor like Maverick Capital can be viewed as a vote of confidence in Rocket Pharmaceuticals, Inc.
• The filing provides transparency regarding the beneficial ownership structure of a notable shareholder.

Negatives

• The document does not contain any negative information regarding Rocket Pharmaceuticals, Inc.

Risks

• The document is a beneficial ownership disclosure and does not explicitly detail specific risks related to Rocket Pharmaceuticals, Inc.

Future Outlook

The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding the issuer's future outlook or financial performance.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing is a routine disclosure of a significant ownership stake by an institutional investor in a publicly traded pharmaceutical company. It reflects an investment position rather than a strategic industry development or operational update.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which can be of interest to other shareholders and the market.

Key Dates

Keywords

Rocket Pharmaceuticals, Maverick Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor